Abstract
We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.
Original language | English (US) |
---|---|
Article number | e00390-17 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 61 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2017 |
Keywords
- Mucormycosis
- Murine
- Prophylaxis
- Rhizopus arrhizus
- VT-1161
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases